Semaglutide Improves Kidney Outcomes in Type 2 Diabetes
FLOW demonstrated that semaglutide reduced kidney and cardiovascular risks in high-risk adults with type 2 diabetes and albuminuric CKD, supporting broader kidney-protective therapy.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.